Nasal microbiome in N-ERD patients treated with dupilumab Raw sequence reads

Here we investigated the impact of dupilumab treatment on composition and diversity of the nasal microbiome using 16S rRNA sequencing in 28 patients suffering from NSAID-exacerbated respiratory disease (N-ERD) before and 4, 8 and 12 weeks after Dupilumab therapy. More than 70% of the samples did not pass quality control, this warrants further refinement of nasal microbiome sampling techniques and mandatory guidelines on stringent quality control for analysis of this low biomass data in the future. Furthermore, dupilumab did not have an impact on microbiome diversity or abundance. This is the first study investigating the microbiome during dupilumab therapy in the context of NSAID-exacerbated disease. Sequencing was performed at the Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna under the project IDs JMF-2111-09 and JMF-2306-01.